These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 27899497)

  • 1. The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.
    Rodbard HW; Peters AL; Slee A; Cao A; Traina SB; Alba M
    Diabetes Care; 2017 Feb; 40(2):171-180. PubMed ID: 27899497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.
    Henry RR; Thakkar P; Tong C; Polidori D; Alba M
    Diabetes Care; 2015 Dec; 38(12):2258-65. PubMed ID: 26486192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
    Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Ways K; Desai M; Shaw W; Capuano G; Alba M; Jiang J; Vercruysse F; Meininger G; Matthews D;
    Diabetes Care; 2015 Mar; 38(3):403-11. PubMed ID: 25468945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF; Xie J; Sherman SE; Garceau C
    Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
    Danne T; Cariou B; Buse JB; Garg SK; Rosenstock J; Banks P; Kushner JA; McGuire DK; Peters AL; Sawhney S; Strumph P
    Diabetes Care; 2019 May; 42(5):919-930. PubMed ID: 30833371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
    Pfeifer M; Townsend RR; Davies MJ; Vijapurkar U; Ren J
    Cardiovasc Diabetol; 2017 Feb; 16(1):29. PubMed ID: 28241822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults With Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial.
    Polonsky WH; Hessler D; Ruedy KJ; Beck RW;
    Diabetes Care; 2017 Jun; 40(6):736-741. PubMed ID: 28389582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
    Rosenstock J; Aggarwal N; Polidori D; Zhao Y; Arbit D; Usiskin K; Capuano G; Canovatchel W;
    Diabetes Care; 2012 Jun; 35(6):1232-8. PubMed ID: 22492586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
    Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
    Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLYCEMIC EFFECTS OF SGLT-2 INHIBITOR CANAGLIFLOZIN IN TYPE 1 DIABETES PATIENTS USING THE DEXCOM G4 PLATINUM CGM.
    Argento NB; Nakamura K
    Endocr Pract; 2016 Mar; 22(3):315-22. PubMed ID: 26523624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
    Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
    Mathieu C; Dandona P; Phillip M; Oron T; Lind M; Hansen L; Thorén F; Xu J; Langkilde AM;
    Diabetes Care; 2019 Jun; 42(6):1081-1087. PubMed ID: 30967434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
    Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
    PLoS One; 2014; 9(9):e110069. PubMed ID: 25268802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study.
    Lee SH; Min KW; Lee BW; Jeong IK; Yoo SJ; Kwon HS; Choi YH; Yoon KH
    Diabetes Metab J; 2021 May; 45(3):339-348. PubMed ID: 32602273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
    Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
    Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
    Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
    Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
    Boeder S; Edelman SV
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):62-77. PubMed ID: 31081593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond HbA1c.
    Bloomgarden Z
    J Diabetes; 2017 Dec; 9(12):1052-1053. PubMed ID: 28792665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.